WuXi STA has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus, bringing the total reactor volume for solid-phase peptide synthesis to over 10,000 L. It has also added a new system that features 300-DAC twin columns for continuous purification of kilogram-scale peptides and oligonucleotides, with faster turnaround times and lower solvent consumption.
Bachem has signed a new framework agreement to provide large volumes of peptides to an unnamed customer following a joint development project. This covers “a committed volume at an equivalent value of over CHF 500 million for the five-year period of 2027-2031, with significant upside potential,” the company said.
This follows recent deals a previous large-volume contract for another unnamed customer worth CHF 175 million in 2023-4. The deal was announced in September 2022 and subsequently upgraded with a further work order for a minimum total of CHF 1 billion from 2025 to 2029.
CordenPharma has signed a multi-year agreement for the contract manufacture of a large-volume launch peptide at its former Roche facility in Boulder, Colorado. This will begin in 2023 and will potentially be worth about $1 billion, depending on actual production levels required. The customer has not been named and no further details are being disclosed.
Bachem has signed a further work order with an unnamed customer for large volumes of peptides for a minimum total of CHF 1 billion from 2025 to 2029. This follows two previous large-volume contracts announced in September worth CHF 175 million in 2023-4. No further details will be disclosed.
Peptides giant Bachem has agreed to acquire an undeveloped site covering 155,000 m2 in Sisslerfeld, north-western Switzerland, from DSM in order to manage growing demand. It has already acquired the first plot and others will follow in time. Terms are not being disclosed.
Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.
WuXi AppTec has announced a plan to build a new R&D and manufacturing site in Singapore at a cost of up to $1.4 billion. It will be created in stages over the next ten years, depending on the company’s business needs.
The company added that the site will serve “a critical role in its global network across Asia, Europe and North America”. It ill include “laboratories and facilities that provide a broad portfolio of R&D and manufacturing services” for the pharmaceutical industry.